What are the clinical phases of acute kidney injury (AKI)?

Clinical Phases of Acute Kidney Injury

AKI evolves through four distinct temporal phases that extend beyond the initial injury: initiation, extension, maintenance, and recovery—with the critical recognition that apparent recovery may mask ongoing subclinical damage that drives progression to chronic kidney disease.

The Four-Phase Framework

Phase 1: Initiation (0-24 hours)

The initiation phase represents the hyperacute injury period where the kidney first encounters the insult 1. This phase is characterized by:

• Bioenergetic collapse with mitochondrial dysfunction and ATP depletion
• Oxidative stress and early inflammatory priming
• Microvascular and metabolic failure 1
• The injury trigger is identifiable (sepsis, nephrotoxin, ischemia, etc.)

Clinical significance: This is the window where prevention strategies are most effective, but injury may not yet be detectable by serum creatinine 2.

Phase 2: Extension/Acute Response (1-7 days)

This phase represents persistent AKI and is dominated by active cellular injury 3:

• Coordinated cell death through multiple pathways (pyroptosis, apoptosis, necroptosis—termed "PANoptosis")
• Ferroptosis (lipid peroxidation-driven cell death)
• Impaired mitophagy (clearance of damaged mitochondria)
• Aberrant G2/M cell cycle arrest preventing proper repair
• Amplified cytokine release and inflammatory cascade 1, 3

Clinical significance: This corresponds to KDIGO stages 1-3 AKI. Persistent AKI (lasting >48 hours) carries significantly worse prognosis than transient AKI 4.

Phase 3: Maintenance/Acute Kidney Disease (7 days to 90 days)

The 2017 ADQI consensus formally defined Acute Kidney Disease (AKD) as the period from 7-90 days after AKI initiation 5. This phase involves:

• Maladaptive repair mechanisms with persistent TGF-β/SMAD signaling
• Metabolic reprogramming toward glycolysis
• Endothelial rarefaction (loss of capillaries)
• Stabilization of pro-fibrotic pathways
• Epigenetic injury memory through chromatin remodeling 3

AKD Staging Framework 5:

• Stage 0A: Serum creatinine returned to baseline, no evidence of ongoing damage, but retained vulnerability
• Stage 0B: Creatinine at baseline BUT evidence of ongoing injury (new proteinuria, hypertension, loss of renal reserve, positive biomarkers)
• Stage 0C: Creatinine elevated but <1.5× baseline (incomplete functional recovery)
• Stage 0B/C: Creatinine not at baseline AND evidence of ongoing injury
• Stages 1-3: Mirror AKI staging (creatinine 1.5×, 2×, 3× baseline respectively)

Critical caveat: Serum creatinine returning to baseline does NOT equal complete recovery 5. Patients may have ongoing tubular injury, loss of renal reserve, or reduced nephron mass despite "normal" creatinine—this is why Stage 0B exists 5.

Phase 4: Recovery or Progression to CKD (Beyond 90 days)

After 90 days, persistent kidney dysfunction is classified as CKD 5, 6. This phase features:

• Irreversible extracellular matrix deposition
• Chronic hypoxia and immune dysregulation
• Established myofibroblast phenotypes perpetuating fibrosis 3

Outcomes from AKD 5:

1. Complete recovery (Stage 0A)
2. Partial recovery with ongoing risk (Stage 0B/C)
3. Progression to CKD
4. Recurrent AKI episodes
5. Death

Key Clinical Implications

The AKI-AKD-CKD Continuum

AKD is conceptualized as post-AKI, not pre-CKD 5. This distinction is critical because:

• Even patients with "complete" creatinine recovery remain at increased risk for CKD, cardiovascular disease, and mortality 5, 6
• The transition from AKI to CKD can occur even when creatinine normalizes 5
• Interventions during the AKD phase may modify long-term outcomes 5

Limitations of Creatinine-Based Assessment

The guidelines explicitly acknowledge that serum creatinine is an inadequate marker of recovery 5 because:

• Loss of muscle mass alters creatinine production
• Volume changes affect distribution
• Hyperfiltration in remaining nephrons can mask nephron loss
• Loss of renal reserve is not detected 5

Follow-up Recommendations

All patients with moderate-to-severe AKI require post-discharge follow-up 7. The timing should be risk-stratified:

• Stage 3 AKI: Early post-discharge follow-up (within weeks)
• Stage 1-2 AKI: 3-month follow-up may be appropriate, though risk of overwhelming clinicians with mild stage 1 cases exists 7
• Pediatric patients: Earlier follow-up is advisable given longer life expectancy and higher stakes of missing nascent CKD 7
• Highest risk: Pre-existing CKD + AKI, or those developing worsening CKD post-AKI 7

Common Pitfalls to Avoid

1. Assuming creatinine normalization equals complete recovery: Always assess for proteinuria, hypertension, and loss of renal reserve 5

2. Missing subclinical AKI: Biomarkers may detect injury before creatinine rises 2

3. Ignoring the temporal nature of pathophysiology: Interventions effective in one phase may be ineffective or harmful in another 3

4. Failing to recognize AKD without documented AKI: A patient presenting with elevated creatinine and history of recent illness may have AKD even without documented AKI episode 5

Practical Assessment During Each Phase

Initiation phase: Monitor high-risk patients with biomarkers if available; optimize hemodynamics and avoid nephrotoxins

Extension phase: KDIGO staging; assess for persistent vs. transient AKI at 48 hours 4

AKD phase: Beyond creatinine, evaluate for:

• New or worsening proteinuria
• New or worsening hypertension
• Biomarkers of ongoing injury
• Renal reserve testing (if available) 5

Recovery/CKD phase: Long-term nephrology follow-up; CKD risk factor modification

This phase-based understanding moves beyond simple staging to recognize AKI as a temporally dynamic continuum requiring phase-appropriate interventions and long-term surveillance 3.